FDA turns down once-a-day version of J&J HIV pill

NEW YORK

Johnson & Johnson said Tuesday the Food and Drug Administration has not approved its application to market a once-per-day version of its HIV pill Prezista and wants more information.

The company said it is reviewing the FDA's response to its marketing application for an 800-milligram Prezista pill, and it plans to respond as quickly as possible. Johnson & Johnson said it does not expect to have to run any new clinical trials of the drug.

Regulators approved the 400-milligram version of Prezista in 2006.

Shares of Johnson & Johnson lost 18 cents to $62.33 in afternoon trading.